Clinical Trial Update: Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms [Phase 3]

View source ↗

Summary

Phase 3 trial update indicates Vagifem Low Dose for postmenopausal vaginal atrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause
• Postmenopausal Vaginal Atrophy

Drugs mentioned

• Vagifem Low Dose (estradiol (vaginal tablet))

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Menopause, Postmenopausal Vaginal Atrophy | Phase 3 | Status: COMPLETED